We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
+$36.9M
Cap. Flow %
1%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.88%
2 Miscellaneous 7.67%
3 Consumer Discretionary 6.51%
4 Financials 0.7%
5 Materials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
101
Solid Biosciences
SLDB
$897M
$5.25M 0.14%
200,000
– –
MIR icon
102
Mirion Technologies
MIR
$3.81B
$5.24M 0.14%
+500,000
New +$5.37M
SYRE icon
103
Spyre Therapeutics
SYRE
$8.02B
$4.96M 0.13%
41,800
– –
ACIU icon
104
AC Immune
ACIU
$266M
$4.95M 0.13%
1,000,000
– –
SNTI icon
105
Senti Biosciences Holdings
SNTI
$9.34M
$4.93M 0.13%
50,000
– –
CYCN
106
DELISTED
Cyclerion Therapeutics
CYCN
$4.78M 0.13%
138,956
– –
GDS icon
107
GDS Holdings
GDS
$6.1B
$4.72M 0.13%
100,000
– –
IQ icon
108
iQIYI
IQ
$965M
$4.56M 0.12%
1,000,000
– –
CRDF icon
109
Cardiff Oncology
CRDF
$104M
$4.51M 0.12%
750,000
– –
ME
110
DELISTED
23andMe Holding Co
ME
$4.4M 0.12%
+33,050
New +$6.1M
BBIO icon
111
BridgeBio Pharma
BBIO
$13.4B
$4.17M 0.11%
250,000
– –
CFRX
112
DELISTED
ContraFect Corporation
CFRX
$3.94M 0.11%
18,750
– –
PHAT icon
113
Phathom Pharmaceuticals
PHAT
$660M
$3.93M 0.11%
+200,000
New +$4.71M
CGEM icon
114
Cullinan Oncology
CGEM
$1.32B
$3.86M 0.1%
250,000
+150,000
+150% +$2.99M
PFTA
115
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.78M 0.1%
380,000
– –
APLT
116
DELISTED
Applied Therapeutics
APLT
$3.58M 0.1%
400,000
– –
TCRR
117
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.5M 0.09%
750,000
– –
RXRX icon
118
Recursion Pharmaceuticals
RXRX
$1.74B
$3.43M 0.09%
200,000
– –
YI
119
111 Inc
YI
$30.7M
$3.38M 0.09%
96,635
– –
IMMP
120
Immutep
IMMP
$48.7M
$3.28M 0.09%
1,000,000
– –
WVE icon
121
Wave Life Sciences
WVE
$879M
$3.14M 0.09%
1,000,000
– –
FUSN
122
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$3.13M 0.08%
750,000
– –
KDNY
123
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.94M 0.08%
180,500
– –
ARAV
124
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.87M 0.08%
1,311,291
– –
LITS
125
Lite Strategy Inc
LITS
$37.1M
$2.67M 0.07%
50,000
– –
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.